Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models.

[1]  R. Chen,et al.  TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. , 2007, American journal of hypertension.

[2]  Masaki Mogi,et al.  Calcium Channel Blocker Azelnidipine Reduces Glucose Intolerance in Diabetic Mice via Different Mechanism Than Angiotensin Receptor Blocker Olmesartan , 2006, Journal of Pharmacology and Experimental Therapeutics.

[3]  T. Fujimura,et al.  A Selective Peroxisome Proliferator-Activated Receptor γ Modulator with Distinct Fat Cell Regulation Properties , 2006, Journal of Pharmacology and Experimental Therapeutics.

[4]  G. Mancia,et al.  Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial , 2006, Journal of hypertension.

[5]  Nathan R. Qi,et al.  Telmisartan But Not Valsartan Increases Caloric Expenditure and Protects Against Weight Gain and Hepatic Steatosis , 2006, Hypertension.

[6]  U. Kintscher,et al.  Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. , 2005, Diabetes.

[7]  Karim Bouzakri,et al.  Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. , 2005, Diabetes.

[8]  R. Chen,et al.  Deletion of Angiotensin II Type 2 Receptor Exaggerated Atherosclerosis in Apolipoprotein , 2005 .

[9]  Jean-Daniel Zucker,et al.  Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. , 2005, Diabetes.

[10]  Y. Hirata,et al.  Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. , 2005, Endocrinology.

[11]  W. Garvey,et al.  Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation Published, JLR Papers in Press, April 16, 2005. DOI 10.1194/jlr.M400373-JLR200 , 2005, Journal of Lipid Research.

[12]  R. Chen,et al.  Fluvastatin Enhances the Inhibitory Effects of a Selective AT1 Receptor Blocker, Valsartan, on Atherosclerosis , 2004, Hypertension.

[13]  K. Shimamoto,et al.  Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. , 2004, Journal of hypertension.

[14]  J. Laragh,et al.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial , 2004, The Lancet.

[15]  Jian-Mei Li,et al.  Angiotensin II Type-1 Receptor Blocker Valsartan Enhances Insulin Sensitivity in Skeletal Muscles of Diabetic Mice , 2004, Hypertension.

[16]  S. Mathur,et al.  Angiotensin II–Induced Vascular Dysfunction Is Mediated by the AT1A Receptor in Mice , 2004, Hypertension.

[17]  M. Lorenzo,et al.  Tumor Necrosis Factor α Produces Insulin Resistance in Skeletal Muscle by Activation of Inhibitor κB Kinase in a p38 MAPK-dependent Manner* , 2004, Journal of Biological Chemistry.

[18]  A. Daugherty,et al.  Angiotensin II-mediated development of vascular diseases. , 2004, Trends in cardiovascular medicine.

[19]  Jian-Mei Li,et al.  Regulation of inhibitory protein-kappaB and monocyte chemoattractant protein-1 by angiotensin II type 2 receptor-activated Src homology protein tyrosine phosphatase-1 in fetal vascular smooth muscle cells. , 2004, Molecular endocrinology.

[20]  M. Desai,et al.  Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.

[21]  K. Wellen,et al.  Obesity-induced inflammatory changes in adipose tissue. , 2003, The Journal of clinical investigation.

[22]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[23]  P. Froguel,et al.  Globular Adiponectin Protected ob/ob Mice from Diabetes and ApoE-deficient Mice from Atherosclerosis* , 2003, The Journal of Biological Chemistry.

[24]  S. Kihara,et al.  Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice , 2002, Circulation.

[25]  Arya M. Sharma,et al.  Angiotensin blockade prevents type 2 diabetes by formation of fat cells. , 2002, Hypertension.

[26]  Philippe Froguel,et al.  Disruption of Adiponectin Causes Insulin Resistance and Neointimal Formation* , 2002, The Journal of Biological Chemistry.

[27]  M. Matsuda,et al.  Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 , 2002, Nature Medicine.

[28]  Arya M. Sharma,et al.  Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. , 2002, Diabetes.

[29]  V. Dzau.  Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. , 2001, Hypertension.

[30]  Masaki Sugiura,et al.  Angiotensin II Type 1a Receptor-deficient Mice with Hypotension and Hyperreninemia (*) , 1995, The Journal of Biological Chemistry.

[31]  G. King,et al.  Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes , 2007, Nature Clinical Practice Endocrinology &Metabolism.